Treatment of a newly diagnosed glioblastoma harboring MET amplification with vebreltinib in combination with radiotherapy: a case report

MET-amplified glioblastoma (GBM) is rare, accounting for approximately 2-5% of cases. However, the treatment regimens for patients with MET-amplified GBM still have not reached a unanimous consensus. Our paper describes the use of vebreltinib in a newly diagnosed glioblastoma patient harboring MET amplification. This successful case study suggests that novel targeted MET inhibitors may provide potential clinical benefits in select cases on the basis of the MET signaling pathway status.